This review discusses the rational for further studies of COX-2 inhibitors-NO releaser hybrids (NO-Coxibs) in the pharmacological treatment of the airway inflammation in Cystic Fibrosis (CF). Our research group developed several classes of NO-Coxibs for the pharmacological treatment of arthritis, and among them several compounds showed an outstanding in vivo efficacy and good pharmacokinetic properties. The good antiinflammatory properties displayed by these compounds during the previous screening could, by itself, suggest appropriate candidates for further testing in CF.
Therapeutic potential for coxibs-nitric oxide releasing hybrids in cystic fibrosis / Consalvi S.; Poce G.; Ghelardini C.; Di Cesare Mannelli L.; Patrignani P.; Bruno A.; Anzini M.; Calderone V.; Martelli A.; Testai L.; Giordani A.; Biava M.. - In: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0223-5234. - ELETTRONICO. - (2020), pp. 0-0. [10.1016/j.ejmech.2020.112983]
Therapeutic potential for coxibs-nitric oxide releasing hybrids in cystic fibrosis
Ghelardini C.;Di Cesare Mannelli L.;Biava M.
2020
Abstract
This review discusses the rational for further studies of COX-2 inhibitors-NO releaser hybrids (NO-Coxibs) in the pharmacological treatment of the airway inflammation in Cystic Fibrosis (CF). Our research group developed several classes of NO-Coxibs for the pharmacological treatment of arthritis, and among them several compounds showed an outstanding in vivo efficacy and good pharmacokinetic properties. The good antiinflammatory properties displayed by these compounds during the previous screening could, by itself, suggest appropriate candidates for further testing in CF.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S0223523420309557-main.pdf
accesso aperto
Descrizione: articolo principale
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
753.23 kB
Formato
Adobe PDF
|
753.23 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
